Banlota, Daisy A.
HRN: 15-36-30 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
07/15/2024
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
07/15/2024
07/22/2024
IV
4.5g
Q8
Breast Mass
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes